Top

Published in:

01-09-2018 | Clinical Study

Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009–2014

Authors: Steinbjørn Hansen, Birthe Krogh Rasmussen, René Johannes Laursen, Michael Kosteljanetz, Henrik Schultz, Bente Mertz Nørgård, Rikke Guldberg, Kim Oren Gradel

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

Background

As many glioblastoma patients are in a poor condition they are unable to undergo the full treatment documented in clinical trials. We aimed to examine the survival and its relationship to clinical characteristics and treatment in a nationwide population of glioblastoma patients in Denmark.

Methods

We included prospectively recorded clinical data from 1364 adult patients with histologically verified glioblastoma from the Danish Neuro-Oncology Registry, 2009–2014.

Results

The age standardized incidence rate was 6.3/100,000 person-years for males and 3.9 for females and the median age was 66 years. The median overall survival was 11.2 months. There was an independently significant prognostic effect of age, performance status, cognitive symptoms, tumor diameter, multifocality, crossing midline, and contrast enhancement. For partial and total resection compared to biopsy only, the adjusted risk of dying was reduced by 43% (HR [CI] 0.57 [0.48–0.68]) and 51% (0.49 [0.40–0.60]), respectively. For patients receiving a partial and full radiochemotherapy regimen compared to no postsurgical treatment, the risk reduction was 56% (HR [CI] 0.44 [0.37–0.53]) and 70% (0.30 [0.25–0.35]), respectively. The full radiochemotherapy regimen was only allocated to 50% of the patients, 29% among the oldest (70+ years) and 60% among the younger (18–69 years).

Conclusions

Glioblastoma patients had a poor overall survival but with several specific independent prognostic factors. Extensive cancer treatment was associated with an increasing survival in all age groups, but only half of the patients were sufficiently fit for a full regimen of postoperative combined radiochemotherapy.

Available only for authorised users

Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C et al (2017) CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 17(S5):iv1–iv88

Asklund T, Malmström A, Bergqvist M, Björ O, Henriksson R (2015) Brain tumors in Sweden: data from a population-based registry 1999–2012. Acta Oncol 54(3):377–384CrossRefPubMed

Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J (2003) Debulking or biopsy of malignant glioma in elderly people—a randomised study. Acta Neurochir 145:5–10CrossRefPubMed

Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC et al. (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576CrossRefPubMed

Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL et al (2016) Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2(11):1460–1469CrossRefPubMed

Laperriere N, Zuraw L, Cairncross G (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64(3):259–273CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMed

Perry JR, Laperriere N, O’Callaghan CJ et al (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037CrossRefPubMed

Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U et al (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95(3):401–411CrossRefPubMed

10.

Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B et al (2011) French brain tumor database: 5-year histological results on 25,756 cases. Brain Pathol 21(6):633–644CrossRefPubMed

11.

Hansen S (2016) The Danish Neuro-Oncology Registry. Clin Epidemiol 8:629–632CrossRefPubMedPubMedCentral

12.

Hansen S, Nielsen J, Laursen RJ, Rasmussen BK, Nørgård BM, Gradel KO et al (2016) The Danish Neuro-Oncology Registry: establishment, completeness and validity. BMC Res Notes 9(1):425CrossRefPubMedPubMedCentral

13.

Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 14(2):97–109CrossRef

14.

Schmidt M, Pedersen L, Sørensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29(8):541–549CrossRefPubMed

15.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655CrossRefPubMed

16.

Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, Nørgård BM et al (2017) Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the Danish Neuro-Oncology Registry. J Neurooncol 135(3):571–579CrossRefPubMed

17.

Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H et al (2017) Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol 131(3):525–546CrossRefPubMed

18.

Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins VP (2015) Glioblastoma in England: 2007–2011. Eur J Cancer 51(4):533–542CrossRefPubMed

19.

Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2015) The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. J Neurooncol 121(2):359–364CrossRefPubMed

20.

Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K et al (2006) Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol 8(1):12–26CrossRefPubMedPubMedCentral

21.

Magrini SM, Ricardi U, Santoni R, Krengli M, Lupattelli M, Cafaro I et al (2006) Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. Int J Radiat Oncol Biol Phys 65(3):788–799CrossRefPubMed

22.

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190–198CrossRefPubMed

23.

Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115(1):3–8CrossRefPubMed

24.

Rønning PA, Helseth E, Meling TR, Johannesen TB (2012) A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Oncol 14(9):1178–1184CrossRefPubMedPubMedCentral

25.

Malmström A, Grønberg BH, Marosi C, Nordic Clinical Brain Tumour Study Group (NCBTSG) et al. (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926CrossRefPubMed

26.

Wick W, Platten M, Meisner C et al (2012) NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13(7):707–715CrossRefPubMed

27.

Rusthoven CG, Koshy M, Sher DJ, Ney DE, Gaspar LE, Jones BL et al (2016) Combined-modality therapy with radiation and chemotherapy for elderly patients with glioblastoma in the temozolomide era: a national cancer database analysis. JAMA Neurol 73(7):821–828CrossRefPubMed

28.

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefPubMed

Title: Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009–2014
Authors: Steinbjørn Hansen
Birthe Krogh Rasmussen
René Johannes Laursen
Michael Kosteljanetz
Henrik Schultz
Bente Mertz Nørgård
Rikke Guldberg
Kim Oren Gradel
Publication date: 01-09-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2892-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009–2014

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas

Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?

Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED10

IDH1 mutation in human glioma induces chemical alterations that are amenable to optical Raman spectroscopy

Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design

Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?